Stock Evaluator: IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences, Inc. IDYA

$40.17 0.50 1.25%

August 24, 2026 11:31:07 AM EST Volume: 354,187

After Hours: $120.37 0.15 | 0.12% November 10, 2021 7:59 PM EST Volume: 72,713

USD NASD | DELAYED PRICE

SECTOR	INDUSTRY
Health Care	Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:

COMPANY SUMMARY

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Commentary & Analysis

Comparison

Which Is a Better Investment, IDEAYA Biosciences, Inc. or Xencor, Inc. Stock?

Learn more about whether IDEAYA Biosciences, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Jenna Brashear

Earnings

What You Need to Know About IDEAYA Biosciences, Inc.'s Q3 Earnings

IDEAYA Biosciences, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (IDYA) missed or beat analyst's expectations.

Tudor Pop

Comparison

Which Is a Better Investment, CareDx, Inc. or IDEAYA Biosciences, Inc. Stock?

Learn more about whether CareDx, Inc. or IDEAYA Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Rosalio Madrigal

Overvalued

Is IDEAYA Biosciences, Inc. (IDYA) Overvalued?

We dive into why IDEAYA Biosciences, Inc. (IDYA) could be considered overvalued on 2026-07-31, based on AAII’s Value Score and Grade.

Rosalio Madrigal

Price

Why IDEAYA Biosciences, Inc.’s (IDYA) Stock Is Down 6.43%

As of Wednesday, July 08, IDEAYA Biosciences, Inc.’s IDYA share price has dipped by 6.43%, which has investors questioning if this is right time to buy.

Cynthia McLaughlin

Financial Summary

Share Statistics	IDYA	Industry Median	Percentile (All Stocks)
Market Cap (Mil)	$3,827.7	$292.6	63%
Shares Out (Mil)	92.1	54.4	60%
Institutional Ownership	99.1%	93.2%	85%
Float (Mil)	90.6	40.2	59%
Beta	-0.09	0.94	4%
Avg Daily Volume (000s)	710	544	64%
Price Change (52-week)	63.1%	59.7%	83%

Growth	IDYA	Industry Median	Percentile (All Stocks)
Sales (5yr)	62.2%	13.6%	97%
Net Income (5yr)	(26.9%)	(10.1%)	16%
EPS (5yr)	1.7%	16.0%	33
Dividends (5yr)	0.0%	0.0%	0%
Cash Flow (5yr)	(27.0%)	(15.6%)	23%

Estimates	Qtrly	Current Fiscal Year	Next Fiscal Year
# of Estimates	13	13	13
Current EPS	($1.174)	($4.611)	($4.108)
Month Ago EPS	($1.049)	($4.284)	($3.653)
# Rev Up	0	0	0
# Rev Down	0	2	2
Three Months Ago EPS	($1.100)	($4.431)	($3.701)
Year/Year Chg	(3.8%)	258.8%	160.7%

Financials	IDYA	Industry Median	Percentile (All Stocks)
Sales (TTM) (Mil)	$234	$37	33%
Net Income (TTM) (Mil)	($175)	($43)	7%
EPS (TTM)	($1.956)	($1.400)	14%
Operating Cash Flow (TTM) (Mil)	($112)	($31)	6%
Net Cash Flow (TTM) (Mil)	$158	$2	81%
Long-Term Debt (Q1) (Mil)	$28	$4	35%
Enterprise Value (Q1) (Mil)	$2,264	$164	51%

Valuation	IDYA	Industry Median	Percentile (All Stocks)
P/B	3.19	2.83	66%
P/E	na	19.6	na
Dividend Yield	0.0%	0.0%	0%
PEG (5yr hist)	na	1.0	na

Ratios	IDYA	Industry Median	Percentile (All Stocks)
Gross Margin	(36.4%)	64.2%	3%
Net Margin	(74.8%)	(75.9%)	9%
ROA	(14.9%)	(47.5%)	22%
ROE	(16.2%)	(55.0%)	25%
Liabilities to Assets	8.5%	29.6%	5%
F-Score	3	3	18%

Passing Stock Screens

As of 8/21/2026, from a list of 60 stock screening strategies, IDYA meetings the criteria of 1 screen:

Stock Screen

FACTOR STRATEGY

Est Rev: Down 5% Screen

Factors: Earnings Estimates

Introduction to the use of earnings estimates.

Performance Since Inception:	2.4%
+/- S&P 500:	-5.1

Passing Stocks

Adient plc	ADNT
4D Molecular Therapeutics, Inc.	FDMT
Achieve Life Sciences, Inc.	ACHV
Alpha Tau Medical Ltd.	DRTS
Annexon, Inc.	ANNX

See All 61 Stocks (as of 8/21/2026)

Stock Evaluator: IDEAYA Biosciences, Inc. (IDYA) + Follow This Stock

IDEAYA Biosciences, Inc. (IDYA )